Estrogen receptor residues required for stereospecific ligand recognition and activation

被引:15
作者
Bocchinfuso, WP [1 ]
Korach, KS [1 ]
机构
[1] NIEHS,RECEPTOR BIOL SECT,REPROD & DEV TOXICOL LAB,NIH,RES TRIANGLE PK,NC 27709
关键词
D O I
10.1210/me.11.5.587
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mouse estrogen receptor (mER) has been shown to exhibit stereospecific binding of certain stilbene estrogen agonists. The region of the mER involved in the stereochemical recognition of ligands was further defined using a stilbene isomer, Indenestrol B (IB). The IB compound has a chiral carbon bearing an ethyl substituent, and the wild type uterine mER has been shown to bind the enantiomers, IB-S and IB-R, with similar affinity. The wild type mER expressed in yeast exhibited a very minor preference for IB-S in transactivation (1.5-fold lower half-maximal dose than IB-R). The IB enantiomers could then be used to determine whether stereochemically distinct compounds with similar transcriptional activity utilize different amino acids in AF-2 for transactivation. Mutant mERs with glycine substitutions at Met521, His528, Met532, and Val537 were expressed in yeast and measured for IB-S- and IB-R-induced transactivation and ligand binding. The M532G mER showed a 124-fold and 50-fold reduction in transactivation induced by IB-S and IB-R, respectively, without a corresponding change in their ligand-binding affinities. Therefore, Met532 is required for transactivation induced by both IB enantiomers but does not discriminate based on stereospecificity. In contrast, the H528G mER displayed a gross change in stereospecific ligand recognition as illustrated by a 11O-fold reduction in transactivation by IB-S and only a 8.8-fold decrease in activity by IB-R. As a result, H528G mER displayed a switch in ligand preference such that IB-R was now 8-fold more active than IB-S in transactivation. Therefore, His528 appears largely involved in transactivation specifically induced by IB-S but has a minimal influence in IB-S ligand binding. The remaining mutant mERs displayed wild type ligand binding and transactivation properties for the IB enantiomers illustrating no stereospecific recognition. These results imply that individual IB enantiomers bind to the mER with similar affinity but utilize at least one different amino acid within the AF-2 domain for signal transduction. The binding of stereochemically distinct ligands may alter the tertiary structure of the mER and cause repositioning of the AF-2 region that mediates transcription of specific genes and/or affect the binding of receptor-associated proteins, such as coactivators, which could influence transcription.
引用
收藏
页码:587 / 594
页数:8
相关论文
共 38 条
[1]   TRANSCRIPTIONAL ACTIVATION BY THE ESTROGEN-RECEPTOR REQUIRES A CONFORMATIONAL CHANGE IN THE LIGAND-BINDING DOMAIN [J].
BEEKMAN, JM ;
ALLAN, GF ;
TSAI, SY ;
TSAI, MJ ;
OMALLEY, BW .
MOLECULAR ENDOCRINOLOGY, 1993, 7 (10) :1266-1274
[2]   CRYSTAL-STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE HUMAN NUCLEAR RECEPTOR RXR-ALPHA [J].
BOURGUET, W ;
RUFF, M ;
CHAMBON, P ;
GRONEMEYER, H ;
MORAS, D .
NATURE, 1995, 375 (6530) :377-382
[3]  
CURTIS SW, 1997, IN PRESS J MOL ENDOC
[4]   IDENTIFICATION OF RESIDUES IN THE ESTROGEN-RECEPTOR THAT CONFER DIFFERENTIAL SENSITIVITY TO ESTROGEN AND HYDROXYTAMOXIFEN [J].
DANIELIAN, PS ;
WHITE, R ;
HOARE, SA ;
FAWELL, SE ;
PARKER, MG .
MOLECULAR ENDOCRINOLOGY, 1993, 7 (02) :232-240
[5]   Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding [J].
Ekena, K ;
Weis, KE ;
Katzenellenbogen, JA ;
Katzenellenbogen, BS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (33) :20053-20059
[6]   ESTROGEN-RECEPTORS, ESTRADIOL, AND DIETHYLSTILBESTROL IN EARLY DEVELOPMENT - THE MOUSE AS A MODEL FOR THE STUDY OF ESTROGEN-RECEPTORS AND ESTROGEN-SENSITIVITY IN EMBRYONIC-DEVELOPMENT OF MALE AND FEMALE REPRODUCTIVE TRACTS [J].
GRECO, TL ;
DUELLO, TM ;
GORSKI, J .
ENDOCRINE REVIEWS, 1993, 14 (01) :59-71
[7]  
GUARENTE L, 1983, METHOD ENZYMOL, V101, P181
[8]   Nuclear receptor coactivators and corepressors [J].
Horwitz, KB ;
Jackson, TA ;
Rain, DL ;
Richer, JK ;
Takimoto, GS ;
Tung, L .
MOLECULAR ENDOCRINOLOGY, 1996, 10 (10) :1167-1177
[9]  
ITO H, 1983, J BACTERIOL, V59, P572
[10]   ENDOCRINE PHARMACOLOGY OF ANTIESTROGENS AS ANTITUMOR AGENTS [J].
JORDAN, VC ;
MURPHY, CS .
ENDOCRINE REVIEWS, 1990, 11 (04) :578-610